30,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
This study implicates ultra-rare, loss-of-function variants in SORL1 as a significant genetic risk factor for Alzheimer's disease and provides a comprehensive dataset comparing the burden of rare variation in nearly all human genes in Alzheimer's disease cases and controls. 4 key findings →
Design: case-control study Participants: 20,197 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A 95% (347/366) concordance rate was noted between clinicians' patient selection and the test's intended use criteria. 5 key findings →
Design: cohort study Participants: 366 Evidence: moderate
Full summary, score breakdown and related studies → Original source
FBXL7, encodes a subcellular protein involved in phosphorylation-dependent ubiquitination processes and displays proapoptotic activity. 5 key findings →
Design: case-control study Participants: 5,300 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Higher chronic exposure to SO2 was associated with a faster decline in memory score, whereas chronic exposure to CO, NO2 , and PM10 were not associated with the rate of cognitive decline. 4 key findings →
Design: longitudinal study Participants: 269 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Longitudinal declines in DCTclock performance, especially in Information Processing involving speed and executive function, were linked to early Aβ and tau burden in preclinical AD. 5 key findings →
Design: cross-sectional Participants: 219 Evidence: moderate
Full summary, score breakdown and related studies → Original source
NfL in both serum and CSF has the potential to serve as a biomarker for clinical disease onset and has a prognostic value in genetic FTD. 1 key finding →
Design: case-control study Participants: 174 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Polygenic Risk Score significantly predicted the risk associated with age at AD onset when SNPs were preselected for association to AD at P ≤ 0.001. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios are significantly better than CSF Aβ42 to detect brain amyloid deposition in prodromal AD and to differentiate AD dementia from non-AD dementias. 5 key findings →
Participants: 1,182 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Widespread implementation of cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) in clinical settings requires improved accuracy for diagnosis of prodromal disease and for distinguishing AD from non-AD dementias. 4 key findings →
Participants: 338 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
To review the optimality and safety of different anti-Amyloid- β (Aβ) immunotherapies for Alzheimer's disease (AD). 3 key findings →
Participants: 5,141 Evidence: high
Full summary, score breakdown and related studies → Original source
A variant in AKAP9, p.R434W, segregated significantly with LOAD in two large families (OR = 5.77, 95% CI: 1.07-30.9, P = 0.041). 5 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Baseline pRBD was associated with faster decline in global cognition and all cognitive domains, including verbal episodic memory, visuospatial ability, executive function, language, and processing speed. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
However, a recent systematic review and meta-analysis did not support differences in orexin-A between AD and controls. 4 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
We developed a robust algorithm to automatically evaluate retinal fundus image that can identify subjects with high WMH burden. 3 key findings →
Design: cross-sectional Participants: 180 Evidence: low
Full summary, score breakdown and related studies → Original source
The novel plasma p-tau181 and p-tau231 assays did not show cross-reactivity. 5 key findings →
Participants: 69 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The study shows individuals with a high APS are more likely than those with a low APS to have abnormal amounts of amyloid plaques and be on an amyloid accumulation trajectory, a dynamic and evolving process characteristic of progressive AD pathology. 1 key finding →
Participants: 13 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Both plasma and CSF measures of Aβ42/Aβ40 and NfL predicted cognitive decline. 4 key findings →
Participants: 371 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Beta-synuclein is a promising cerebrospinal fluid and blood biomarker of synaptic damage. 5 key findings →
Participants: 150 Evidence: low
Full summary, score breakdown and related studies → Original source
Ambient 2-year averaged exposure of PM2.5 was associated with changes of neuroinflammatory markers, that is, CSF sTREM2 (β = -0.116, p = 0.0002). 5 key findings →
Participants: 1,131 Evidence: low
Full summary, score breakdown and related studies → Original source
The score reflecting the severity of Aβ pathology showed a better correlation with ln(Aβ42/Aβ40) (R 2 = 0.506, β = -0.713, P < 0.001) than with ln(Aβ42) (R 2 = 0.206, β = -0.458, P < 0.001), which was confirmed after adjusting for covariates. 4 key findings →
Participants: 159 Evidence: low
Full summary, score breakdown and related studies → Original source
In both cohorts, we observed that tau-PET standardized uptake value ratio in medial temporal lobes was associated with clinical dementia rating Sum of Boxes (CDR-SoB) scores independently of local amyloid-PET uptake (FWE corrected at p < 0.001). 5 key findings →
Participants: 154 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Plasma p-tau181 differentiates AD pathology cases from NC with high accuracy. 4 key findings →
Participants: 91 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Interpretation of axonal damage biomarker Neurofilament Light chain (NfL) concentrations is difficult due to the lack of age-specific and disease-specific reference values. 2 key findings →
Participants: 1,698 Evidence: low
Full summary, score breakdown and related studies → Original source
After expert panel review, only 50/67 patients met consensus criteria for DLB, 26/151 controls had a reduced MoCA, and 120/151 controls had a normal MoCA. 5 key findings →
Design: cross-sectional Participants: 151 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Plasma biomarkers of neuronal injury and astrogliosis are associated with reduced axonal density and region-specific myelin content. 5 key findings →
Participants: 119 Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,180 records, built mostly from automated pulls of Europe PMC (64.2% of the library) and OpenAlex (16.9%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →